Japanese Pharmacology & Therapeutics（JPT）
Vol. 30 Suppl.1 2002
Phase I Study of Single Dose Administration of Telmisartan (BIBR277), an Angiotensin II AT1 Receptor Antagonist
T.Ogihara, et al.
Jpn Pharmacol Ther 2002 30（s1）7
Phase I Study of Multiple Dose Administration of Telmisartan (BIBR277), an Angiotensin II AT1 Receptor Antagonist
T.Ogihara, et al.
Jpn Pharmacol Ther 2002 30（s1）33
Clinical Evaluation of Antihypertensive Effect and Safety of an Angiotensin II AT1 Receptor Antagonist,
BIBR277 (Telmisartan), in Patients with Mild-to-moderate Essential Hypertension
─Pre-pilot Study─
T.Ogihara
Jpn Pharmacol Ther 2002 30（s1）53
Clinical pharmacokinetic study of the ultrasound contrast agent YM454
─Pilot Study─
K.Arakawa, et al.
Jpn Pharmacol Ther 2002 30（s1）63
Clinical Evaluation of Efficacy on the Diurnal Blood Pressure Variation and Safety of an Angiotensin II AT1
Receptor Antagonist, BIBR277 (Telmisartan), in Patients with Essential Hypertension
─Evaluation with Ambulatory Blood Pressure Monitoring─
K.Arakawa, et al.
Jpn Pharmacol Ther 2002 30（s1）83
The Optimal Dose of BIBR277 (Telmisartan), the Long-acting Angiotensin II AT1 Receptor Antagonist, in Patients with Mild-to-moderate Essential Hypertension
K.Arakawa, et al.
Jpn Pharmacol Ther 2002 30（s1）103
Effect on the Combination of BIBR277 (Telmisartan), the Long-acting Angiotensin II AT1 Receptor Antagonist, with Calucium Antagonists or Diuretics in Patients with Mild-to-moderate Essential Hypertension
K.Arakawa, et al.
Jpn Pharmacol Ther 2002 30（s1）121
Safety Evaluation of 52 Weeks Treatment of BIBR277(Telmisartan) , the Long-acting Angiotensin II AT1 Receptor Antagonist, in Patients with Mild-to-moderate Essential Hypertension
K.Arakawa, et al.
Jpn Pharmacol Ther 2002 30（s1）139
Clinical Evaluation of BIBR277(Telmisartan), the Long-acting Angiotensin II AT1 Receptor Antagonist, in Patients with Severe Hypertension
K.Arakawa, et al.
Jpn Pharmacol Ther 2002 30（s1）169
Pharmacokinetics of BIBR277 (Telmisartan) in Hypertensive Patients with Renal Insuffisiency
T.Ogihara, et al.
Jpn Pharmacol Ther 2002 30（s1）183
Influence of Food on the Bioavailability of Single Oral Dose of BIBR277 (Telmisartan)
S.Irie, et al.
Jpn Pharmacol Ther 2002 30(s1) 201
The Long-term Safety of BIBR277 (Telmisartan), the Long-acting Angiotensin II AT1 Receptor Antagonist, in Patients with Mild-to-moderate Essential Hypertension
K.Arakawa, et al.
Jpn Pharmacol Ther 2002 30（s1）209
Pharmacokinetics of BIBR277 (Telmisartan) in Patientswith Essential Hypertension
T.Ogihara, et al.
Jpn Pharmacol Ther 2002 30（s1）235
Efficacy and Safety of BIBR277 (Telmisartan) , the Long-acting Angiotensin II AT1 Receptor Antagonist, in Hypertensives with Renal Insufficiency
K.Abe, et al.
Jpn Pharmacol Ther 2002 30（s1）253
Pharmacokinetic Evaluation of an Angiotensin II AT1 Receptor Antagonist, BIBR277 (Telmisartan) in Hypertensive Patients
T.Ogihara, et al.
Jpn Pharmacol Ther 2002 30（s1）271